Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Gynecol Oncol. 2016 Apr;141(1):65–71. doi: 10.1016/j.ygyno.2016.01.003

Figure 1.

Figure 1

A hypothetical approach to biomarker driven therapy in gynecologic malignancies. While traditionally these cancers would have been grouped together as one type of malignancy (top panel), various molecular signatures could place each cancer in a different molecular category (represented by a different color; bottom panels). These molecular biomarkers could then be used to identify agents to be preferentially used to treat cancers within the given molecular category. Currently, in gynecologic malignancies, the only validated biomarker for targeted therapy treatment is BRCA mutation for PARP inhibitors.